Cancer-associated thrombosis in hematologic malignancies

This article summarizes the current understanding, risk factors, prediction models, and optimal prevention and treatment strategies of CAT in hematologic malignancies on a disease-by-disease basis, including acute leukemia, lymphoma, myeloma, and myeloproliferative neoplasms. Specific considerations of novel molecular targeted therapeutics introduced in recent years, such as immunomodulatory drugs and tyrosine kinase inhibitors, are also discussed based on the latest clinical trials.PMID:38270784 | DOI:10.1007/s12185-023-03690-z
Source: International Journal of Hematology - Category: Hematology Authors: Source Type: research